ライフサイエンスコーパス: aspartate aminotransferase

1 ties (grade 3 diarrhoea and grade 3 elevated aspartate aminotransferase).

2 us co factor for diverse enzymes, among them aspartate aminotransferase.

3 eased levels of alanine aminotransferase and aspartate aminotransferase.

4 and eosin quantification, and serum alanine/aspartate aminotransferase.

5 ABDC active site is very similar to that of aspartate aminotransferase.

6 serum levels of alanine aminotransferase and aspartate aminotransferase.

7 hydrogenase < 100 U/L, below analyzer range; aspartate aminotransferase 0 hour, 15.6 +/- 9.3 U/L vs 7

8 the role of endogenous sulfur dioxide (SO2)/ aspartate aminotransferase 1 (AAT1) pathway in stretch-i

9 573 patients vs six [1%] of 570), increased aspartate aminotransferase (103 [18%] vs 16 [3%]), hyper

10 %] among 68 who received placebo), increased aspartate aminotransferase (11 [8%] vs two [3%]), anaemi

11 e (15%), alanine aminotransferase (12%), and aspartate aminotransferase (11%).

12 dL), alanine aminotransferase (2288.82 U/L), aspartate aminotransferase (1251.76 U/L), gamma-glutamyl

13 %] of 573 vs one [<1%] of 570) and increased aspartate aminotransferase (14 [2%] vs one [<1%]).

14 quent grade 3-4 adverse events were elevated aspartate aminotransferase (14 of 44, 32%), elevated gam

15 enzymes (alanine aminotransferase, 657 U/L, aspartate aminotransferase, 1401 U/L), blood urea (53 mg

16 lanine aminotransferase compared to group B (aspartate aminotransferase, 168[166] vs. 57[67] IU/L; P=

17 vs six [0.9%]), and reversible increases in aspartate aminotransferase (22 [3.4%] vs three [0.5%]).

18 sterol, 42.80 mg/dL (39.84-45.76 mg/dL); for aspartate aminotransferase, 22.67 U/L (19.94-25.41 U/L);

19 s of hypertension (35% vs. 15%) and elevated aspartate aminotransferase (23% vs. 8%) were higher with

20 ransferase (73 [30%] patients) and increased aspartate aminotransferase (25 [10%]).

21 nd elevations in alanine aminotransferase or aspartate aminotransferase (25 [12%]).

22 ed with -7.29 (-9.5, -5.1) IU/L; P < 0.001], aspartate aminotransferase [-31.33 (-32.1, -30.5) compar

23 group, SG induced significant improvement in aspartate aminotransferase (32.4 +/- 17.4 vs 21.5 +/- 6.

24 in alanine aminotransferase (7 [11.3%] SAD), aspartate aminotransferase (4 [6.5%] SAD), and creatinin

25 minotransferase (ALT) (-49%; P = 0.009), and aspartate aminotransferase (-42%; P = 0.019).

26 288 patients vs four [3%] of 140), elevated aspartate aminotransferase (51 [18%] vs four [3%]), hype

27 nine aminotransferase (ALT) (-67% and -60%), aspartate aminotransferase (-57% and -52%), and fibrogen

28 levels of alanine aminotransferase (64%) and aspartate aminotransferase (60%), hypoalbuminemia (55%),

29 Mean postoperative day (POD) 7, aspartate aminotransferase (61.13 + 24.77 vs 73.17 + 53.

30 mia (86 [34%]), fatigue (83 [33%]), elevated aspartate aminotransferase (65 [26%]), and increased ala

31 0 IU/L alanine aminotransferase and 420 IU/L aspartate aminotransferase 9 hours after gavage.

32 Importantly, increasing peak perioperative aspartate aminotransferase, a surrogate marker of hepati

33 Consistently, inhibition of aspartate-aminotransferase, a key enzyme of the shunt, i

34 In aspartate aminotransferase (AAT), an extended hydrogen b

35 SO2 synthase aspartate aminotransferase (AAT1 and AAT2) mRNA and prot

36 nalysis (fibrosis, alanine aminotransferase, aspartate aminotransferase, age, biopsy length).

37 ed plasma glucose, alanine aminotransferase, aspartate aminotransferase, AGEs and insulin levels.

38 ur algorithm included data on age; levels of aspartate aminotransferase, alanine aminotransferase (AL

39 aspartate aminotransferase, alanine aminotransferase (AL

40 of serum liver tests (alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase) an

41 (international normalized ratio, bilirubin, aspartate aminotransferase, alanine aminotransferase) an

42 of hepatocyte injury and cholestasis (serum aspartate aminotransferase, alanine aminotransferase, bi

43 ic diagnoses and laboratory values (albumin, aspartate aminotransferase, alanine aminotransferase, cr

44 easily available perfusate parameters (PP) (aspartate aminotransferase, alanine aminotransferase, la

45 o routine markers of liver impairment (e.g., aspartate aminotransferase, alanine aminotransferase, la

46 Mean aspartate aminotransferase, alanine aminotransferase, to

47 occur in previous studies showing increased aspartate aminotransferase-alanine aminotransferase rati

48 is and a substantially higher AUROC than the aspartate aminotransferase-alanine aminotransferase rati

49 ients with diabetes, and those with elevated aspartate aminotransferase/alanine aminotransferase (AST

50 on age, viral genotype, initial viral load, aspartate aminotransferase/alanine aminotransferase rati

51 outcome in multivariate analyses were higher aspartate aminotransferase/alanine aminotransferase rati

52 s the elevation in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and ga

53 ean difference for alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and ga

54 olesterol, whereas increasing plasma alanine/aspartate aminotransferases (ALT/AST) and hepatic trigly

55 ociated with liver-related complications; an aspartate aminotransferase/ALT ratio >1 and older age we

56 ed NASH as reflected by reductions in plasma aspartate aminotransferase and alanine aminotransferase

57 ose-limiting toxicity (one grade 3 increased aspartate aminotransferase and alanine aminotransferase

58 ing induction (20 [54%] patients), increased aspartate aminotransferase and alanine aminotransferase

59 higher mean [+/-2 standard deviation] serum aspartate aminotransferase and alanine aminotransferase

60 ma and liver triglyceride content and plasma aspartate aminotransferase and alanine aminotransferase

61 iversity displayed significantly higher mean aspartate aminotransferase and alanine aminotransferase

62 r, and skeletal muscle and had higher plasma aspartate aminotransferase and alanine aminotransferase,

63 score created from the platelet count, serum aspartate aminotransferase and alanine aminotransferase,

64 pect to sex, age, duration of disease, serum aspartate aminotransferase and alkaline phosphatase leve

65 During therapy, aspartate aminotransferase and alkaline phosphatase leve

66 proportion of patients alanine transaminase, aspartate aminotransferase and AlkPhos >5x upper-limit-o

67 sis, decreased platelet count, and increased aspartate aminotransferase and alpha-fetoprotein levels

68 cyte population, depleted KCs, and increased aspartate aminotransferase and creatine kinase serum enz

69 learance of several serum enzymes, including aspartate aminotransferase and creatine kinase, that are

70 ture, decreased apoptosis, and reduced serum aspartate aminotransferase and creatinine levels compare

71 tients; one patient had grade 3 increases in aspartate aminotransferase and gammaglutamyltransferase

72 Aspartate aminotransferase and lactate dehydrogenase as

73 preserved kidneys showed significantly lower aspartate aminotransferase and lactate dehydrogenase lev

74 bilirubin and alanine aminotransferase; POD3 aspartate aminotransferase and prothrombin time-internat

75 yde-3-phosphate dehydrogenase, aldolase, and aspartate aminotransferase and thus reactivates these pr

76 e 3 increase of alanine aminotransferase and aspartate aminotransferase) and two (13%) patients given

77 (current hematocrit, albumin, total protein, aspartate aminotransferase), and baseline demographics a

78 chemistries, including alkaline phosphatase, aspartate aminotransferase, and bilirubin, were signific

79 and elevated levels of blood urea nitrogen, aspartate aminotransferase, and creatinine.

80 pids, cholesterol, alanine aminotransferase, aspartate aminotransferase, and creatinine.

81 speptidase, maximum alanine aminotransferase/aspartate aminotransferase, and fibrosis stage were asso

82 concentrations of alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyltransferas

83 increases in alanine aminotransferase and in aspartate aminotransferase, and hyponatraemia, each occu

84 rboxylase NAD-ME, a mitochondrial isoform of aspartate aminotransferase, and photorespiratory markers

85 er of kidney injury (P = 0.01), lower plasma aspartate aminotransferase, and reduced rate of troponin

86 y-4-cholesten-3-one, bile acids, alanine and aspartate aminotransferases, and neoepitope-specific N-t

87 vate carboxylase, alanine, and an isoform of aspartate aminotransferase are localized in the cytosol.

88 d predictive clinical variables and revealed aspartate aminotransferase as an important, albeit previ

89 /tissue volume (BV/TV) by micro-CT analysis; aspartate aminotransferase (ASAT) and alanine aminotrans

90 ctivity of PLP in both GabR and a homologous aspartate aminotransferase (Asp-AT) from Escherichia col

91 nternal aldimine in alanine racemase (AlaR), aspartate aminotransferase (AspAT), and poly-L-lysine.

92 ansferases (PPA-ATs) that belong to class-Ib aspartate aminotransferases (AspAT Ibs) and catalyze the

93 of NASH in elderly patients included higher aspartate aminotransferase (AST) (odds ratio [OR] = 1.12

94 with both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (P < 0.0001, analysis o

95 h K8/18/Ub foci (r(2) = 0.47, P < 0.001) and aspartate aminotransferase (AST) (r(2) = 0.15, P = 0.002

96 ysophosphatidylcholines were associated with aspartate aminotransferase (AST) 14-day post-transplanta

97 Aspartate aminotransferase (AST) activity at LT (hazard

98 mitted COVID-19 patients had elevated plasma aspartate aminotransferase (AST) and 35% had elevated al

99 Aspartate aminotransferase (AST) and alanine aminotransf

100 Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and fetuin-A were deter

101 They found that an increase in aspartate aminotransferase (AST) and its dynamicity corr

102 The increase of aspartate aminotransferase (AST) by >25% (hazard ratio [

103 ed by pure fructose) increases liver fat and aspartate aminotransferase (AST) concentrations in healt

104 eiver operating characteristics curve showed aspartate aminotransferase (AST) had highest area under

105 of vomiting, lower platelet count, elevated aspartate aminotransferase (AST) level, positivity in th

106 d lower serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels and less hepatic

107 Nine studies evaluated associations between aspartate aminotransferase (AST) levels and T2D risk, wi

108 g NMP grafts showed significantly lower peak aspartate aminotransferase (AST) levels than those recei

109 ibrosis in these patients were defined using aspartate aminotransferase (AST) levels, fibrosis-4 (FIB

110 the lower alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, less liver dama

111 fibrosis score determined by FibroSURE with aspartate aminotransferase (AST) measurements and HIV co

112 ension with grade 3 rash and fevers, grade 4 aspartate aminotransferase (AST) or alanine aminotransfe

113 The primary endpoint was postoperative aspartate aminotransferase (AST) peak value; early graft

114 163-HCV-FS was significantly superior to the aspartate aminotransferase (AST) to platelet ratio index

115 cerides, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) using a general linear

116 analysis older patient's age, abnormal serum aspartate aminotransferase (AST) value, Hepatitis C viru

117 Median aspartate aminotransferase (AST) was higher than alanine

118 nd plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were increased in wildt

119 According to reported data, patients with aspartate aminotransferase (AST)>100 IU/L and 50 IU/L sh

120 The serum levels of aspartate aminotransferase (AST), alanine aminotransfera

121 induced Liver Damage (MALD) uses a patient's aspartate aminotransferase (AST), alanine aminotransfera

122 injury was assessed by the levels of plasma aspartate aminotransferase (AST), alanine aminotransfera

123 Peak values of aspartate aminotransferase (AST), alanine aminotransfera

124 hepatotoxicity with improved blood levels of aspartate aminotransferase (AST), alanine transaminase (

125 um levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (

126 ses in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (

127 ood glucose, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase,

128 e (GGT), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), among a discovery set

129 d nephropathy with alanine aminotransferase, aspartate aminotransferase (AST), and bilirubin levels <

130 nd change in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl tra

131 Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltran

132 Transplant albumin, day-1 aspartate aminotransferase (AST), day-1 lactate, day-3 b

133 ate dehydrogenase, alanine aminotransferase, aspartate aminotransferase (AST), gamma-glutamyltransfer

134 od levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), glucose, total cholest

135 the upper limit of normal (ULN), platelets, aspartate aminotransferase (AST), hemoglobin, sodium, pa

136 tal protein, alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase

137 ved testing for the total enzyme activity of aspartate aminotransferase (AST), lactate dehydrogenase

138 iabetes, hypertension, hypertriglyceridemia, aspartate aminotransferase (AST), platelets, and the hom

139 lular carcinoma (HCC) and the performance of aspartate aminotransferase (AST)-platelet ratio index (A

140 Aspartate aminotransferase (AST)-to-platelet ratio (APRI

141 We evaluated the diagnostic accuracy of aspartate aminotransferase (AST)-to-platelet ratio index

142 less severe steatosis on biopsy, lower serum aspartate aminotransferase (AST)/alanine aminotransferas

143 sex, high levels of TBL, and a high ratio of aspartate aminotransferase (AST):ALT were independent ri

144 aminotransferase (42 versus 27, P = 0.005), aspartate aminotransferase (AST; 26 versus 21, P = 0.01)

145 etween both eprotirome groups and placebo in aspartate aminotransferase (AST; p<0.0001), alanine amin

146 ng semiannual follow-up with LFTs, including aspartate-aminotransferase (AST), alanine aminotransfera

147 Plasma aminotransferases (aspartate aminotransferase [AST] and alanine aminotransf

148 fined by changes in liver aminotransferases (aspartate aminotransferase [AST] and alanine aminotransf

149 es (e.g., alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) were compared between

150 Clinical characteristics, liver tests (aspartate aminotransferase [AST], alanine aminotransfera

151 ver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transpe

152 Our analysis sought to validate APRI (aspartate aminotransferase [AST]-to-platelet ratio index

153 Four variables (platelet count, aspartate aminotransferase [AST]/alanine aminotransferas

154 antly superior to biochemical markers (e.g., aspartate aminotransferase [AST]/platelet ratio, FIB-4,

155 atelet ratio (APRI) was calculated as = 100*(aspartate aminotransferase [AST]/upper limit of AST)/pla

156 te aminotransferase-to-platelet ratio index (aspartate aminotransferase [AST]: platelet index), AST:a

157 ver function (alkaline phosphatase, ALP, and aspartate aminotransferase, AST) and total serum protein

158 FT abnormality was defined as an increase in aspartate aminotransferase, (AST), alanine aminotransfer

159 (SD) decreases for alanine transaminase and aspartate aminotransferase at week 12 compared to the ba

160 l, the G allele was associated directly with aspartate aminotransferase (beta = 2.60; 95% CI: 0.99, 4

161 sfunction, supported by elevations in plasma aspartate aminotransferase, blood urea nitrogen, and cre

162 Alanine aminotransferase, aspartate aminotransferase, BMI, insulin, Quantitative I

163 f-function mutation of the cytosolic form of aspartate aminotransferase (Caa1).

164 ificantly higher in group 2, conversely mean aspartate aminotransferase, cholinesterases, and prothro

165 progression (18 [6%] vs 11 [4%]), increased aspartate aminotransferase concentration (15 [5%] vs 23

166 ration (24 [21%] vs one [1%]), and increased aspartate aminotransferase concentration (16 [14%] vs on

167 [19%] vs one [1%]) and increased alanine or aspartate aminotransferase concentration (39 [10%] vs no

168 oncentrations (two [7%] patients), increased aspartate aminotransferase concentration (two [7%] patie

169 ase concentrations (74 [46%]), and increased aspartate aminotransferase concentrations (65 [41%]).

170 in serum triglycerides (eight patients) and aspartate aminotransferase concentrations (two patients)

171 Elevated alanine and aspartate aminotransferase concentrations and profound e

172 weight, height, alanine aminotransferase or aspartate aminotransferase concentrations, or alcohol us

173 lel biochemical pathways, namely alanine and aspartate aminotransferases, could not compensate for th

174 y decreased serum levels of both alanine and aspartate aminotransferases, decreased hepatic necrosis,

175 cificity of three aminotransferases (E. coli aspartate aminotransferase, E. coli branched-chain amino

176 .5%) and reversible alanine aminotransferase/aspartate aminotransferase elevations (13.4%).

177 ded neutropenia, thrombocytopenia, increased aspartate aminotransferase, febrile neutropenia, and tum

178 re of NtdA shows that NtdA shares the common aspartate aminotransferase fold (Type 1) with residues f

179 aminotransferase (five [6%]), and increased aspartate aminotransferase (four [5%]).

180 In Study 2, 16 g/d increased mean aspartate aminotransferase from baseline (19 U/L; 95% CI

181 eductions in serum alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase,

182 aline phosphatase; alanine aminotransferase; aspartate aminotransferase; gamma-glutamyltransferase; a

183 can be confounded in the setting of abnormal aspartate aminotransferase, gammaglutamyl transpeptidase

184 Increased aspartate aminotransferase, gammaglutamyl transpeptidase

185 The aspartate aminotransferase gene AAT1 was found to be a c

186 linked to the tricarboxylic acid cycle (eg, aspartate aminotransferase [Got2] and hydroxyacid-oxoaci

187 findings, O2 saturation lower than 90%, and aspartate aminotransferase greater than 40 U/L.

188 r Hy's criteria (alanine aminotransferase or aspartate aminotransferase greater than three times the

189 nd/or levels of alanine aminotransferase and aspartate aminotransferase >30 mU/L, using magnetic reso

190 Histologic features, plasma aspartate aminotransferase, hepatic cytokine profile, ox

191 Seventy-two hrs after reperfusion, plasma aspartate aminotransferase, hepatic oxidative stress, me

192 ated levels of lactate dehydrogenase in 82%, aspartate aminotransferase in 70%, alanine aminotransfer

193 e in two patients at 20 mg/kg, and increased aspartate aminotransferase in one patient at 1 mg/kg, an

194 Median peak aspartate aminotransferase in the first 7 days was signi

195 eased levels of alanine aminotransferase and aspartate aminotransferase in the plasma, indicating les

196 otransferase in two (8%) patients, increased aspartate aminotransferase in two (8%) patients, decreas

197 apoptosis, and activity of serum alanine and aspartate aminotransferases in wild-type mice.

198 (in 12%), alkaline phosphatase (in 21%), and aspartate aminotransferase (in 27%).

199 Hair colour changes (67%), fatigue (54%), aspartate aminotransferase increase (39%), nausea (38%),

200 increase (five [14%]), pyrexia (four [11%]), aspartate aminotransferase increase (three [8%]), and ej

201 Ewing sarcoma, three [7%] for osteosarcoma), aspartate aminotransferase increase (two [4%] for Ewing

202 reated patients, with pneumonitis, increased aspartate aminotransferase, increased alanine aminotrans

203 Conversion of aspartate aminotransferase into tyrosine aminotransferas

204 ex, elevated serum alanine aminotransferase, aspartate aminotransferase, iron, transferrin-iron satur

205 GTK/KAT I and aspartate aminotransferase/KAT IV possess cysteine S-con

206 For instance, l-aspartate aminotransferase (l-AspAT) is inactivated by 4

207 nternational normalized ratio <= 1, baseline aspartate aminotransferase level <= 49 U/L, and a decrea

208 e aminotransferase level (in 11%), increased aspartate aminotransferase level (in 9%), hyponatremia (

209 range, 39-99 U/L [0.65-1.65 ukat/L]), and an aspartate aminotransferase level of 88 U/L (1.47 ukat/L)

210 (normal range, 0-29 U/L [0-0.48 ukat/L]), an aspartate aminotransferase level of 98 U/L (1.6 ukat/L)

211 (normal range, 0-29 U/L [0-0.48 ukat/L]), an aspartate aminotransferase level of 98 U/L (1.6 ukat/L)

212 ants, primarily those with a higher ratio of aspartate aminotransferase level to platelet count.

213 hrombocytopenia (70 [14%] of 490), increased aspartate aminotransferase levels (22 [5%]), and anaemia

214 demonstrated by decreased serum alanine and aspartate aminotransferase levels and numbers of TUNEL-p

215 y reduced serum alanine aminotransferase and aspartate aminotransferase levels as well as proinflamma

216 eight and serum alanine aminotransferase and aspartate aminotransferase levels at week 24 (P < 0.05).

217 e also found that plasma creatine kinase and aspartate aminotransferase levels in Acsl1(M) (-/-) mice

218 Serum alanine and aspartate aminotransferase levels were reduced with vita

219 Serum aspartate aminotransferase levels were the only clinical

220 nd creatinine, alanine aminotransferase, and aspartate aminotransferase levels were within normal lim

221 mice with recombinant IL-22 decreased serum aspartate aminotransferase levels, ameliorated cardinal

222 A levels, serum alanine aminotransferase and aspartate aminotransferase levels, and hepatic inflammat

223 independently associated with HBV DNA load, aspartate aminotransferase levels, and platelet counts;

224 inotransferase levels, four (33%) had raised aspartate aminotransferase levels, and two (17%) had inc

225 se rates, serum alanine aminotransferase and aspartate aminotransferase levels, or longitudinal chang

226 elevated serum alanine aminotransferase and aspartate aminotransferase levels.

227 ld higher serum alanine aminotransferase and aspartate aminotransferase levels.

228 The screen yielded GOT1, the cytosolic aspartate aminotransferase, loss of which kills cells up

229 increases (40% alanine aminotransferase, 17% aspartate aminotransferase), maculopapular rash (17%), a

230 rane fatty acid transporter as mitochondrial aspartate aminotransferase (mAsp-AT) indicated that the

231 creatine phosphokinase (n=2), and increased aspartate aminotransferase (n=2) each occurring in more

232 commonly reversible increases in alanine or aspartate aminotransferase) occurred in six (3%), two (1

233 nine aminotransferase of 63.9%, P<0.005; and aspartate aminotransferase of 45.0%, P<0.005) and increa

234 proaches to show that Rv3722c is the primary aspartate aminotransferase of M. tuberculosis, and media

235 Minimal parenchymal damage (aspartate aminotransferase) of the liver was seen after

236 e round of DNA back-shuffling with wild-type aspartate aminotransferase on this variant generated mut

237 placebo 18.2%; p = 0.355) or adverse events (aspartate aminotransferase or alanine aminotransferase >

238 xclusion criteria were other liver diseases, aspartate aminotransferase or alanine aminotransferase c

239 grade 3-4 increases in levels of alanine or aspartate aminotransferases or bilirubin; there were no

240 ncreased levels of alanine aminotransferase, aspartate aminotransferase, or gamma-glutamyl transferas

241 ed concentrations of asymptomatic alanine or aspartate aminotransferase, or gamma-glutamyltransferase

242 lu457Lys) of ALDH2, and two traits including aspartate aminotransferase (P = 5.20 x 10(-13)) and alan

243 h markers of hepatic inflammation (P=.02 for aspartate aminotransferase, P=.002 for ferritin) and fib

244 vasive indices for ruling out cirrhosis: the aspartate aminotransferase-platelet ratio index (APRI) a

245 sis, the platelet count, age-platelet index, aspartate aminotransferase-platelet ratio index (APRI),

246 Based on aspartate aminotransferase/platelet ratio index and FIB-

247 luronic acid measurement but superior to the aspartate aminotransferase/platelet ratio index, FIB-4 s

248 or 2 of the following: NAFLD fibrosis score, aspartate aminotransferase/platelet ratio index, FIB-4 s

249 3) and 20.9 (95% CI: 2.6-165.3) based on the aspartate aminotransferase/platelet ratio index; and 6.2

250 For example, aspartate aminotransferase protonates the pyridine nitro

251 na that control the electronic modulation in aspartate aminotransferase.Pyridoxal 5'-phosphate (PLP)

252 alkaline phosphatase (R = 0.543, P = 0.003), aspartate aminotransferase (R = 0.420, P = 0.029), and l

253 /- 77 U/L in the placebo group; P = .02) and aspartate aminotransferase (reduction, 31 +/- 52 vs 4 +/

254 Moreover, cellular injury demonstrated by aspartate aminotransferase release and cell death is les

255 oadipate aminotransferase, and mitochondrial aspartate aminotransferase, respectively.

256 nd AAT2 encoding mitochondrial and cytosolic aspartate aminotransferases, respectively; (iii) MDH1 an

257 erapy, based on alanine aminotransferase and aspartate aminotransferase response criteria, and more l

258 ic activity was associated with higher serum aspartate aminotransferase, rs12979860 IL28B genotype, a

259 (affecting >/=2% of patients) were elevated aspartate aminotransferase (six [2%] vs none), dyspnoea

260 , hyponatraemia (11 [6%] vs 0) and increased aspartate aminotransferase (six [3%] vs five [5%]).

261 seven [7%]), and increased concentration of aspartate aminotransferase (six [3%] vs two [2%]).

262 l homology with members of the PLP-dependent aspartate aminotransferase subfamily.

263 old types of pyridoxal phosphate enzymes: an aspartate aminotransferase subgroup 1beta in tested alph

264 l fold places it into the well-characterized aspartate aminotransferase superfamily.

265 tures place them into the well-characterized aspartate aminotransferase superfamily.

266 Grade 3 increased aspartate aminotransferase, syncope, pericardial effusio

267 ethnicity, sex, alcohol, cirrhosis, ratio of aspartate aminotransferase to alanine aminotransferase,

268 h the inactive K258A mutant of PLP-dependent aspartate aminotransferase to give a stable external ald

269 luated the utility of two simple biomarkers, aspartate aminotransferase to platelet ratio index (APRI

270 culated: NASH clinical scoring system (NCS), aspartate aminotransferase to platelet ratio index (APRI

271 of 3-year liver stiffness measurement (LSM), aspartate aminotransferase to platelet ratio index (APRI

272 mined by the NAFLD fibrosis score (NFS), the aspartate aminotransferase to platelet ratio index (APRI

273 f liver disease, fibrosis-4 (FIB-4), and the aspartate aminotransferase to platelet ratio index (APRI

274 ors and the decline or increase of FIB-4 and aspartate aminotransferase to platelet ratio index (APRI

275 assessed non-invasively via the serum tests Aspartate Aminotransferase to Platelet Ratio Index and H

276 level >/=3 times the upper limit of normal, aspartate aminotransferase to platelet ratio index score

277 kin 28B genotype, negatively associated with aspartate aminotransferase-to platelet ratio index, and

278 Liver fibrosis was predicted using the aspartate aminotransferase-to-platelet ratio index (APRI

279 ld vs. nonmild), defining mild disease as an aspartate aminotransferase-to-platelet ratio index (APRI

280 We used the aspartate aminotransferase-to-platelet ratio index (APRI

281 m (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI

282 cohort and outperformed the Mayo Clinic and aspartate aminotransferase-to-platelet ratio index (APRI

283 OMA-IR) and liver fibrosis defined using the aspartate aminotransferase-to-platelet ratio index (APRI

284 tic resonance imaging and MRE, FIBROSpectII, aspartate aminotransferase-to-platelet ratio index (aspa

285 ore than or equal to stage 1 groups, whereas aspartate aminotransferase-to-platelet ratio index and A

286 , liver function test, complete blood count, aspartate aminotransferase-to-platelet ratio index and t

287 al cutoffs for three noninvasive biomarkers (aspartate aminotransferase-to-platelet ratio index, Fibr

288 er waist circumference, levels of alanine or aspartate aminotransferase, total and low-density lipopr

289 elevation of serum alanine aminotransferase, aspartate aminotransferase, total bilirubin and direct b

290 This consists of an aspartate aminotransferase (TvAspAT1), which transaminat

291 erase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two

292 [5%]) and increased concentrations of serum aspartate aminotransferase (two [10%]) in cohort B.

293 10%]), and increased concentrations of serum aspartate aminotransferase (two [10%]).

294 Aspartate aminotransferase was significantly higher in D

295 Serum alanine aminotransferase and aspartate aminotransferase were increased by all three c

296 lar injury markers lactate dehydrogenase and aspartate aminotransferase were persistently low (lactat

297 Serum levels of both alanine and aspartate aminotransferases were also lower after intrap

298 d both the elevation in plasma IFN-gamma and aspartate aminotransferase, whereas depletion of CD8(+)

299 igher levels of alanine aminotransferase and aspartate aminotransferase, whereas the diagnosis of SH

300 cture of a homodimeric PLP-dependent enzyme, aspartate aminotransferase, which was reacted in situ wi